New drug duo takes on tough bile duct cancer in first-line trial

NCT ID NCT07369791

Not yet recruiting Disease control Sponsor: National Health Research Institutes, Taiwan Source: ClinicalTrials.gov ↗

First seen Jan 31, 2026 · Last updated May 24, 2026 · Updated 18 times

Summary

This study tests whether adding two immunotherapy drugs (nivolumab and relatlimab) to standard chemotherapy can shrink tumors better than one immunotherapy drug plus chemo in people with advanced bile duct cancer. About 76 adults who have not had prior treatment for their advanced cancer will take part. The main goal is to see how many patients have their tumors shrink or disappear.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED BILIARY TRACT CANCER(BTC) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

China Medical University Hospital

Taichung, Taiwan
Kaohsiung Medical University Chung-Ho Memorial Hospital,

Kaohsiung City, Taiwan
MacKay Memorial Hospital

Taipei, Taiwan
National Cheng Kung University Hospital

Tainan, Taiwan
National Taiwan University Hospital

Taipei, Taiwan
Taichung Veterans General Hospital

Taichung, Taiwan
Taipei Veterans General Hospital

Taipei, Taiwan
Tri-Service General Hospital

Taipei, Taiwan

Conditions

Explore the condition pages connected to this study.

ADVANCED BILIARY TRACT CANCER(BTC)